Novo Holdings
Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
Xellia Pharmaceuticals
Acquisition in 2013
Xellia Pharmaceuticals ApS is a specialty pharmaceutical company headquartered in Copenhagen, Denmark, focused on developing, manufacturing, and supplying anti-infective products for the global market. Established in 1959, the company specializes in both fermented and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms (FDF). Xellia is recognized as a leading supplier of Vancomycin and Colistimethate Sodium, providing clinically effective treatments for serious bacterial and antibiotic-resistant infections as well as certain fungal diseases. The company operates four manufacturing facilities in Hungary, China, and the United States, adhering to current Good Manufacturing Practice (cGMP) standards and regulatory approvals from authorities such as the US Food and Drug Administration. Xellia also offers a range of contract manufacturing services, including custom synthesis for clinical trials and large-scale production, while continually expanding its product range to address evolving treatment needs. With over 850 employees, Xellia serves more than 700 customers across over 70 countries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.